Beijing-based Novogene Technology Co., Ltd., a commercial provider of genomic services and solutions with next-generation sequencing (NGS) and bioinformatics expertise, has completed a $75 Million (RMB515 Million) Series B round financing led by China Merchants Bank Co., Ltd.’s CMB International Capital Management (Shenzhen) Co., Ltd. (CMB International).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
